Drug Regulator Warns Against Indiscriminate Painkiller, Antibiotic Use Over Kidney Risks

India’s drug regulator has issued a warning against the indiscriminate use of painkillers and antibiotics, highlighting their potential association with chronic kidney disease and stressing the need for appropriate medical supervision.

The Central Drugs Standard Control Organization issued a circular dated September 21 advising the public, healthcare professionals, pharmacists, retailers, wholesalers and healthcare institutions to ensure that non-steroidal anti-inflammatory drugs, or NSAIDs, and antibiotics are used only when clinically indicated and under appropriate medical advice.

NSAIDs are commonly used as painkillers and include several medicines prescribed or purchased for conditions involving pain and inflammation. The CDSCO noted that most NSAIDs are classified under Schedule H of India’s Drugs Rules and should not be sold at retail without a prescription from a registered medical practitioner.

The regulator also highlighted that most antibiotics fall under Schedule H1 and carry prescription requirements and warnings regarding their use.

The circular specifically cautions against taking painkillers or antibiotics indiscriminately, repeatedly or for prolonged periods without medical advice. It also advises against using antibiotics for self-medication or for conditions where they are not clinically indicated.

The warning is important because inappropriate medicine use can create multiple public-health problems.

For antibiotics, unnecessary use can contribute to antimicrobial resistance, making certain bacterial infections more difficult to treat. Taking antibiotics for viral illnesses, for example, does not provide treatment for the underlying viral infection.

Painkillers present a different set of concerns. NSAIDs can have adverse effects, particularly when used at inappropriate doses, for prolonged periods or by people with certain underlying health conditions.

The CDSCO’s circular specifically connects indiscriminate use of NSAIDs and antibiotics with concerns around chronic kidney disease. The regulator has therefore asked stakeholders to ensure that these medicines are used at the appropriate dose and for the appropriate duration.

The directive is also aimed at pharmacists and retailers. Prescription medicines should not be supplied outside the conditions specified under India’s drug regulations.

For consumers, the message is not that painkillers or antibiotics should never be used. Both categories have important medical applications when prescribed appropriately.

The concern is unsupervised, repeated or prolonged use without proper clinical assessment.

The warning also underlines the importance of patients informing doctors about medicines they are already taking, particularly when treatment continues for an extended period.

Kidney health can be affected by several factors, and medicine use is only one potential contributor. The CDSCO circular is therefore best understood as a regulatory warning about inappropriate medicine use rather than a claim that all NSAID or antibiotic use causes kidney disease.

The regulator has asked multiple stakeholders to strengthen compliance with existing prescription and usage requirements.

The development comes as India continues to confront both antimicrobial resistance and the broader challenge of medication misuse.

For the public, the practical message is straightforward: prescription medicines should be taken according to medical advice, rather than repeatedly self-medicated based on previous prescriptions or symptoms.

The CDSCO’s latest circular places particular emphasis on appropriate indication, dose, duration and professional supervision.